Showing 11-20 of 1745 results for "".
- JAK Inhibitors in Practice - SERIEShttps://practicaldermatology.com/series/jak-inhibitors-in-practice/
What You Missed at San Diego Dermatology Symposium
https://practicaldermatology.com/topics/psoriasis/what-you-missed-at-san-diego-dermatology-symposium/19884/Jashin Wu, MD, founder of San Diego Dermatology Symposium, gives an overview of the 2020 meeting, which went virtual.Heart of the Matter: Effects of Psoriasis Treatment on CV Risks
https://practicaldermatology.com/topics/psoriasis/heart-of-the-matter-effects-of-psoriasis-treatment-on-cv-risks/18747/By Jashin Wu, MD and Seemal R. Desai, MDThere's growing evidence that treatment of psoriasis reduces the risk of CV events, but it's not clear whether this potential benefit should influence treatment decisions. Patient screening and counseling remain important, Dr. Wu says.Psoriasis and Inflammatory Disease Management Today
https://practicaldermatology.com/topics/psoriasis/psoriasis-and-inflammatory-disease-management-today/19885/COVID-19 can have implications for psoriasis management. Jashin Wu, MD, founder of San Diego Dermatology Symposium, provides guidance on management and introduces the Inaugural Symposium for Inflammatory Skin Disease, coming virtually in April.Papa in at Valeant, J&J Acquires Neostrata, Celebrity Lip Envy
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-papa-in-at-valeant-j-j-acquires-neostrata-celebrity-lip-envy/18772/This edition of DermWireTV brings news that Joseph C. Papa has left Perrigo Company plc, a top five global over-the-counter consumer goods and pharmaceutical company, to take the helm as CEO at Valeant Pharmaceuticals. He will replace J. Micheal Pearson. Valeant also concluded its investigation arouThe Complex World of Biosimilars
https://practicaldermatology.com/topics/psoriasis/the-complex-world-of-biosimilars/18633/Jashin Wu, MD, discusses potential concerns with biosimilars, including the chance of inducing variable immunogenic responses compared with reference agents. Although there are currently no biosimilars approved for use in psoriasis in the United States, these agents are fast approaching market availExploring the Complexities of Psoriasis
https://practicaldermatology.com/topics/psoriasis/exploring-the-complexities-of-psoriasis/18553/Biologic therapies developed over the last decade or more to treat psoriasis may do more than clear the skin. Researchers are investigating the effects of treatment on comorbid risks, and comparing treatment with older interventions. Jashin Wu, MD explains.Ortho Dermatologics NDA, J&J Innovation, Consumer Credit Insights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-ortho-dermatologics-nda-j-j-innovation-consumer-credit-insights/18395/Two-thirds of prospective patients say they would be more likely to book a procedure if they were aware of financing options. More than three-quarters of prospective patients are unaware of financing options, according to a recent survey by Zalea. In conjunction with Johnson & Johnson Consumer,DermwireTV: Rinvoq Approved for Pediatric Psoriatic Arthritis; J&J Acquires Novel AD Candidate
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rinvoq-approved-for-pediatric-psoriatic-arthritis/26269/In this week's DermwireTV, the FDA approves Rinvoq for pediatric psoriatic arthritis; Johnson & Johnson acquires an AD candidate for $1.25 billion; and the president of Acclaro Medical discusses the latest FDA clearance of its Ultraclear Laser.DermwireTV: J&J Boosts Dermatology Pipeline; New Humira Biosimilar Launched
https://practicaldermatology.com/programs/practical-dermatology/dermwiretv-jj-boosts-dermatology-pipeline-new-humira-biosimilar-launched/24561/In this episode of DermwireTV, Johnson & Johnson makes a major acquisition to expand its dermatology treatment pipeline; the first high-concentration, citrate-free biosimilar to Humira is launched in the US; and in the C-Suite Chats feature, the CEO of Benev discusses the medical aesthetic marke